Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides.
Conjugate vaccines were prepared with S. aureus type 8 capsular polysaccharide (CP) using three carrier proteins: Pseudomonas aeruginosa exotoxin A (ETA), a non-toxic recombinant ETA (rEPA), and diphtheria toxoid (DTd). Adipic acid dihydrazide (ADH) or N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was used as a spacer to link the CP to carrier protein. All conjugates gave a high immune response with a boost after the second immunization. Conjugates prepared with ADH gave higher antibody titers than conjugates prepared with SPDP. IgG1 was the primary subclass elicited by all conjugates regardless of the carrier protein or the conjugation method used to prepare the vaccines. The non-immunogenic CP and the conjugates were formulated with either monophosphoryl lipid A (MPL), QS21, or in Novasomes and evaluated in mice. While the adjuvants failed to improve the immunogenicity of the nonconjugated CP, a more than fivefold increase in the antibody levels was observed when these adjuvants were used with the conjugates. Significant rises in IgG2b and IgG3 were observed with all formulations. The enhancement of the immunogenicity and the IgG subclass shift, as seen with some adjuvants, may prove to be important in immunocompromised patients.
Fattom
A
A
W.W. Karakawa Microbial Pathogenesis Laboratory, Univax Biologics Inc., Rockville, MD, USA.
Li
X
X
Cho
Y H
YH
Burns
A
A
Hawwari
A
A
Shepherd
S E
SE
Coughlin
R
R
Winston
S
S
Naso
R
R
D036002:ADP Ribose Transferases; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D016667:Bacterial Capsules / Q000276:immunology; D001426:Bacterial Proteins / Q000494:pharmacology; D001427:Bacterial Toxins; D001428:Bacterial Vaccines / Q000494:pharmacology*; D002352:Carrier Proteins / Q000494:pharmacology*; D004168:Diphtheria Toxoid / Q000494:pharmacology; D005098:Exotoxins / Q000494:pharmacology; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D008813:Mice, Inbred ICR; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000494:pharmacology; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; D002352:Carrier Proteins; D004168:Diphtheria Toxoid; D005098:Exotoxins; D007074:Immunoglobulin G; D011135:Polysaccharides, Bacterial; D011994:Recombinant Proteins; D018074:Vaccines, Conjugate; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C064836:capsular polysaccharide, type 8, Staphylococcus aureus